Surveillance of Sensitivity to Penicillin in streptococcus Agalactiae recovered from pregnant women between 35-37 weeks of gestation.
DOI:
https://doi.org/10.31053/1853.0605.v74.n4.16395Keywords:
streptococcus agalactiae, GBS, antimicrobial, penicillin, intrapartum prophylaxisAbstract
Streptococcus agalactiae (GBS) cause severe infections in newborns under three months. Meningitis, pneumonia and sepsis are the main infectious diseases in these children. These infections are among the most serious that an individual can suffer in his first twelve hours of life. The child acquires the infection by vertical transmission of the colonized mother. To prevent neonatal disease, penicillin is recommended as the drug of choice for intrapartum prophylaxis (PIP) in pregnant women colonized. However, strains with decreased susceptibility to penicillin have been detected so it is important to monitor the susceptibility to penicillin to ensure its usefulness during prophylaxis. The aim of this study was to determine the sensitivity to penicillin in GBS strains recovered from pregnant women with 35-37 weeks of gestation. Ninety-six isolates were studied and sensitivity was determined by the epsilometric method Etest® (LIOFILCHEM, Italy), following the recommendations of the Clinical Laboratory Standards Institute (CLSI). Minimum Inhibitory Concentration (MIC) was obtained for each bacterial isolation. 100% (96) of the strains studied were sensitive to penicillin with MIC values between 0.012 and 0.094 ?g mL-1. These results indicate that penicillin remains the antimicrobial of choice during intrapartum prophylaxis, for the prevention of neonatal disease caused by GBS in our region. The importance of epidemiological surveillance of sensitivity to penicillin and other antimicrobials is highlighted in order to alert new resistance mechanisms and to adapt treatment strategies.
Downloads
References
Vergara M, Quiroga M, , Pegels E, Laczeski M, Oviedo P, Rinaldi M. Las infecciones bacterianas y el laboratorio de bacteriología (actualizada y ampliada). 2° ed. Posadas: Editorial Universitaria. Universidad Nacional de Misiones; 2015. [Book]
Kilian M, Greenwood D, Slack R, Peutherer J, Barer M. Medical Microbiology. 17th ed. Amsterdam: Elsevier; 2007.
Abdelghany M, Schenferd L. Group B streptococcal infective endocarditis. J Infect Public Health. 2014; 7:237-239. [PubMed] [Free Article]
Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. Prevalence of maternal group B stretococcal colonisation in European countries. Acta Obstet Gynelcol Scand. 2014; 87:260-271. [PubMed] [Free Article]
Schuchat A. Epidemiology of group B streptococcal disease in de the United States: Shifting paradigms. Clin Microbiol Rev. 1998;11:497-513. [PubMed] [Free Article]
Hannoun A, Shehab M, Khairallah MT, Sabra A, Abi-Rached R, Bazi T, et al. Correlation between group B streptococcal genotypes, their antimicrobial resistance profiles and virulence genes among pregnant women in Lebanon. Int J Microbiol. 2009;2009:796512. doi: 10.1155/2009/796512. [PubMed] [Free Article]
Edwars MS, Baker CJ. Streptococcus agalactiae. En: Dolin R, Mandell GL. Bennett JE. Enfermedades infecciosas. Principios y prácticas. Vol. 2. Elsevier; 2006. p. 2423-2434.
CDC: Center for desease control and prevention. Performance Standards for Antimicrobial Susceptibility Testing; 24th informational Supplement. Atlanta: 2.010. (‘accessed 16 April 2015’). [Article]
Ministerio de Salud. LegiSalud Argentina. En: http://test.e-legis-ar.msal.gov.ar/leisref/public/search.php; consultado el 20/06/2015.
Cunningham F G, Gant N, Levenok, Gilstrap III L, Hauth J, Wenstrom K. Williams. Obstetricia. 21ª ed. Buenos Aires: Editorial Médica Panamericana; 2004.
Steele, Russell W. Microbes. En: http://www.antimicrobe.org/b240.asp#top; consultado el 19/09/2015.
Laczeski M, Pegels E, Oviedo P, Quiroga M, Vergara M. Streptococcus agalactiae, primer estudio en Misiones de genes de resistencia asociados a serotipos capsulares. Rev. cienc. tecnol. 2013; 20:68-74. [Article] [Free Article]
Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, et al. First molecular characterization of Group B Streptococci with reduced Penicillin Susceptibility. Antimicrob Agents Chemother. 2008;52(8):2890-2897. [PubMed] [Free Article]
Dahesh S†, Hensler ME†, Van Sorge N, Gertz Jr RE, Schrag S, Nizet V. Point mutation in the Group B Streptococcal PBP2X Gen conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52(8):2915-2918. [PubMed] [Free Article]
CDC: Center for Disease Control and Prevention Prevention of perinatal group B streptococcal desease. MMWR Morbid Mortal Wkly Rep. 2002;1-22. [Article]
Smaill F. Intrapartum antibiotics for group B streptococcal colonization. Cochrane Database of Sistematic Reviews. 1999;3:1-5. [PubMed] [Free Article]
Betriu C, Gómez M, Sánchez A, Cruceyra A, Romero J, Picazo J. Antibiotic Resistance and Penicillin Tolerance in Clinical Isolates of Group B Streptococci. Antimicrob Agents Chemother. 1994;38(9):2183-2186. [PubMed] [Free Article]
Kimura K, Nagano N, Arakawa Y..Classification of group B Streptococci with reduced ß-lactam susceptibility (GBS-RBS) based on the amino acid substitution in PBPs. J Antimicrob Chemother. 2015;70(6):1601-1603. [PubMed] [Free Article]
Florez J. Farmacología Humana. 3°ed. Barcelona:Masson S.A.;1997.
Procop G, Woods G, et al. Resistencia bacteriana a los antibióticos. En: Winn W, Allen S, Janda W, Doneman E. Diagnóstico microbiológico. 6ª ed. Buenos Aires: Médica Panamericana; 2008. p. 902-919.
MacFaddin JF. Pruebas Bioquímicas para la identificación de bacterias de importancia clínica. Buenos Aires: Editorial Médica Panamericana; 2003.
CLSI: Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Wayne PA: CLSI Guideline M45, 2015.
CLSI: Clinical and Laboratory Standards Institute. Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administratrion Interpretive Criteria (Breakpoints). Tabla 2H-1 Streptococcus spp. B-Hemolytic Group M02 and M07. M100S. 26th ed. Atlanta; 2016.
Di Bartolomeo S, Gentile M, Priore G, Valle S, Di Bella A. Streptococcus agalactiae in pregnant women. Prevalence at the Posadas Hospital. Rev. Argent. Microbiol. 2005;37(3):142-144. [PubMed]
Perez J, Limansky A, Toresani I, Ebner G, Di Bartolomeo S, De Inocenti I, et al. Distribución de tipo capsular y sensibilidad antimicrobiana de Streptococcus agalactiae productores de infecciones en Argentina. Rev. Argent. Microbiol. 2004;36:63-67. [PubMed]
Dutra V, Alves V, Olendzki A, Dias C, Bastos de A, Santos G, et al. Streptococcus
agalactiae in Brazil: serotype distribution, virulence determinants and antimicrobial susceptibility. BMC Infect Dis, 2014;14:323. doi:10.1186/1471-2334-14-323. [PubMed] [Free Article]
Seki T, Kimura K, Reid ME, Miyazaki A, Banno H, Jin W, et al. High isolation rate of MDR group streptococci with reduced penicillin susceptibility in Japan. J Antimicrob Chemother. 2015;70:2725-2728. [PubMed] [Free Article]
Barros R, Jobst R, Souza A F de, Melo A L de, Modino S S B de. Evaluation of Streptococcus agalactiae carriage among high risk pregnant women attended in Niterói, RJ, Brazil. Rev. Patol. Trop. 2015;44(4):386-394.
Crespo-Ortiz M, Catañeda-Ramirez C, Recalde-Bolaños M, Vélez-Londoño J. Emerging trends in invasive and noninvasive isolates of Streptococcus agalactiae in a Latin American hospital: a 17-year study. BMC Infectious Diseases. 2014;14:1-11. [Article]
Kasahara K, Baltus AJ, Lee S-H, Edelstein MA, Edelstein PH. Prevalence of Non-Penicillin-Susceptible Group B Streptococcus in Philadelphia and Specificity of Penicillin Resistance Screening Methods. J Clin Microbiol. 2010;48(4):1468-1469. [PubMed] [Free Article]
Nagano N, Nagano Y, Toyama M, Kimura K, Tamura T, Shibayama K, et al. Nosocomial spread of multidrog-resistant group B streptococci with reduced penicillim susceptibility belonging to clonal complex 1. Antimicrob Chemother. 2012;67:849-856. [PubMed] [Free Article]
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
